December 28, 2005 -- Celgene received FDA approval of Revlimid, its second-generation version of Thalidomide, as a treatment for patients with transfusion dependent anemia due to myelodysplastic syndromes (MDS). Having won approval for the first indication, Celgene will now submit an application for approval of Revlimid as a treatment for multiple myeloma. In an interview, the company president forecast multi-billion dollar sales for the drug, if it wins additional approvals. We look at the drug and its prospects...
